Identification of an inactivating cysteine switch in protein kinase Cε, a rational target for the design of protein kinase Cε-inhibitory cancer therapeutics

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10478-10485

  Chu, Feng ^a   Koomen, John M ^a   Kobayashi, Ryuji ^a   O'Brian, Catherine A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTAMINE; CYSTEINE; DISULFIDE; MUTANT PROTEIN; N ETHYLMALEIMIDE; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; THIOPHENE;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CARCINOGENICITY; CERCOPITHECIDAE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INACTIVATION; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYSIS; CERCOPITHECUS AETHIOPS; CONSERVED SEQUENCE; COS CELLS; CYSTEINE; DIGLYCERIDES; ENZYME ACTIVATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 28544437465     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1989     Document Type: Article

References (32)

1. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
2. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5.
3. Herbst RS, Fukuoka M, Baselga J. Gefitinib: a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65.
4. Warner SL, Bearss DJ, Han H, Von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003;2:589-95.
5. Gray NS, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998;281:533-8.
6. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34.
8. Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004;117:131-2.
9. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996;13:2517-26.
10. Perletti GP, Concari P, Brusaferri S, Marras E, Piccinini F, Tashjian AH, Jr. Protein kinase Cε is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene 1998; 16:3345-8.
11. Soh JW, Weinstein IB. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 2003;278:34709-16.
12. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by α-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Cancer Res 2003;63:3037-42.
13. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Protein kinase C-ε is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-α ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase C-ε transgenic mice. Cancer Res 2003;63:6547-55.
14. Hofmann J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 1997;11:649-69.
15. Brose N, Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 2002;115:4399-411.
16. Rossner S, Fuchsbrunner K, Lange-Dohna C, et al. Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing. J Biol Chem 2004;279:27841-4.
17. Chu F, Chen LH, O'Brian CA. Cellular protein kinase C isozyme regulation by exogenously delivered physiological disulfides: implications of oxidative protein kinase C regulation to cancer prevention. Carcinogenesis 2004;25:585-96.
18. Chu F, O'Brian CA. PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide. Antioxidants Redox Signaling 2005;7:855-62.
19. Chu F, Ward NE, O'Brian CA. PKC isozyme S-cysteinylation by cystine stimulates the pro-apoptotic isozyme PKC δ and inactivates the oncogenic isozyme PKC epsilon. Carcinogenesis 2003;24:317-25.
20. Chu F, Ward NE, O'Brian CA. Potent inactivation of representative members of each PKC isozyme subfamily and PKD via S-thiolation by the tumor-promotion/progression antagonist glutathione but not by its precursor cysteine. Carcinogenesis 2001;22:1221-9.
21. Wheeler DL, Reddig PJ, Dreckschmidt NE, Leitges M, Verma AK. Protein kinase Cδ-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression. Oncogene 2002;21:3620-30.
22. Xu ZB, Chaudhary D, Olland S, et al. Catalytic domain crystal structure of protein kinase C-θ (PKCθ). J Biol Chem 2004;279:50401-9.
23. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995;9:576-96.
24. Humphries KM, Juliano C, Taylor SS. Regulation of cAMP-dependent protein kinase activity by glutathionylation. J Biol Chem 2002;277:43505-11.
25. O'Brian CA, Chu F. Post-translational disulfide modifications in cell signaling: role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. Free Radic Res 2005;39:471-80.
26. Adachi T, Pimentel DR, Heibeck T, et al. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem 2004;279:29857-62.
27. Mohr S, Hallak H, de Boitte A, Lapetina EG, Brune B. Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1999;274:9427-30.
28. Eaton P, Wright N, Hearse DJ, Shattock MJ. Glyceraldehyde phosphate dehydrogenase oxidation during cardiac ischemia and reperfusion. J Mol Cell Cardiol 2002;34:1549-60.
29. Martin F, Penet MF, Malergue F, et al. Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest 2004;113:591-7.
30. Pitari G, Malergue F, Martin F, et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett 2000;483:149-54.
31. Kataoka H, Imamura Y, Tanaka H, Makita M. Determination of cysteamine and cystamine by gas chromatography with flame photometric detection. J Pharm Biomed Anal 1993;11:963-9.
32. Seelig GF, Meister A. Cystamine-Sepharose. A probe for the active site of γ-glutamylcysteine synthetase. J Biol Chem 1982;257:5092-6.